Key facts
- KromaTiD’s last known valuation is $39.0M (Jul 2025).
- It has raised $23.6M across 5 recorded rounds; the latest was Seed Round ($3.6M) in Jul 2025.
- Notable investors include National Institutes of Health, Innosphere Ventures, Colorado Office of Economic Development & International Trade, BroadOak Capital Partners, CSU Starta — 11 tracked in total.
- KromaTiD has filed 8 Form Ds with the SEC since 2013, most recently Jul 2025 ($3.6M sold to 57 investors).
- Status: Privately Held (backing).
Investors
11+- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for KromaTiD
Funding rounds
5 roundsAbout KromaTiD
Developer of next-gen cytogenetic products focused on discovering, detecting, and diagnosing genomic rearrangements in the areas of oncology and rare diseases. The company's molecular cytogenetic and genetracker tests discover, detect, and diagnose the widest range of disease-causing mutations, including inversions and translocations, in a single test, enabling research teams in academia, pharma, and biopharma to accelerate the delivery of novel therapeutics to the patients who need them.
- Sector
- Healthcare
- HQ
- Longmont, CO, United States
- Founded
- 2007
- Employees
- 35
- Website
- kromatid.com/
- Ownership
- Privately Held (backing)
KromaTiD doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KromaTiD shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KromaTiD in its N-PORT filings yet. We sweep new filings monthly.